Home » Author Archives: Catherine Skari

Author Archives: Catherine Skari

FT-4202, FORMA’s Experimental SCD Therapy, Fares Well in Phase 1 Trial of Healthy Volunteers

  FT-4202, FORMA Therapeutics’ experimental disease-modifying therapy for sickle cell disease (SCD), shows a favorable safety and pharmacokinetic profile in healthy volunteers, according to data from a Phase 1 clinical trial. Patient recruitment is open for the second part of the trial (NCT03815695). Information about trial locations, all in the U.S., is available here. ...

Read More »

TIF’s latest Newletter is out now!

Catch up with our most recent newsletter and get informed about TIF’S activities and achievements in the past few months! If you would also like to receive our news directly into your inbox, along with thousands of people across the world, subscribe here!

Read More »